ZYDUS LIFESCIENCES LTD (ZYDUSLIFE) financials
ZYDUS LIFESCIENCES LTD (ZYDUSLIFE) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20.Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus…
- Market Cap: ₹1,12,020Cr.
- Current Price: ₹1,123
- Stock P/E: 30.7
- ROE: 16.5%
- ROCE: 16.6%
- Book Value: ₹235
- Dividend Yield: 0.09%
- 52W High / Low: ₹1,232/836
In Jun 2026, ZYDUS LIFESCIENCES LTD (ZYDUSLIFE) reported sales ₹2,872 Cr and net profit ₹340 Cr.
Annual TTM: sales ₹11,768 Cr, net profit ₹3,515 Cr.
Shareholding: Promoters 75.01% (Sep 2026), FIIs 7.05% (Sep 2026), DIIs 11.28% (Sep 2026), Government 0.00% (Sep 2026), Public 6.66% (Sep 2026).
| Category | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2,621 | 2,516 | 5,820 | 2,588 | 2,871 | 2,284 | 3,741 | 2,872 |
| Expenses | 1,678 | 1,867 | 2,047 | 2,003 | 1,719 | 2,085 | 1,752 | 2,285 |
| Operating Profit | 942 | 648 | 3,773 | 585 | 1,152 | 199 | 1,989 | 587 |
| OPM % | 36% | 26% | 65% | 23% | 40% | 9% | 53% | 20% |
| Other Income | 327 | 78 | 185 | 157 | 542 | 414 | 388 | 124 |
| Interest | 96 | 97 | 155 | 138 | 114 | 116 | 116 | 103 |
| Depreciation | 134 | 132 | 128 | 130 | 136 | 144 | 151 | 152 |
| Profit before tax | 1,039 | 497 | 3,675 | 475 | 1,444 | 352 | 2,111 | 456 |
| Tax % | 24% | 5% | 23% | 19% | 20% | 16% | 18% | 25% |
| Net Profit | 790 | 471 | 2,814 | 385 | 1,157 | 296 | 1,722 | 340 |
| EPS in Rs | 7.85 | 4.68 | 27.96 | 3.82 | 11.49 | 2.95 | 17.11 | 3.40 |
| Raw PDF | — | — | — | — | — | — | — | — |
| Category | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 6,347 | 7,780 | 7,837 | 8,732 | 10,819 | 15,116 | 11,484 | 11,768 |
| Expenses | 4,916 | 5,468 | 5,916 | 6,277 | 6,760 | 7,380 | 7,559 | 7,841 |
| Operating Profit | 1,432 | 2,312 | 1,921 | 2,454 | 4,059 | 7,736 | 3,925 | 3,927 |
| OPM % | 23% | 30% | 25% | 28% | 38% | 51% | 34% | 33% |
| Other Income | 848 | -102 | -144 | 345 | 1,076 | 696 | 1,501 | 1,467 |
| Interest | 234 | 71 | 135 | 278 | 391 | 464 | 483 | 448 |
| Depreciation | 429 | 451 | 479 | 489 | 504 | 524 | 561 | 583 |
| Profit before tax | 1,617 | 1,688 | 1,164 | 2,032 | 4,240 | 7,445 | 4,382 | 4,363 |
| Tax % | 13% | 13% | 26% | 25% | 19% | 22% | 19% | — |
| Net Profit | 1,413 | 1,476 | 858 | 1,529 | 3,442 | 5,775 | 3,560 | 3,515 |
| EPS in Rs | 13.80 | 14.42 | 8.38 | 15.11 | 34.20 | 57.39 | 35.38 | 34.95 |
| Dividend Payout % | 25% | 24% | 30% | 40% | 9% | 19% | 3% | — |
| Category | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 102 | 102 | 102 | 102 | 101 | 101 | 101 | 101 |
| Reserves | 8,467 | 11,158 | 12,642 | 13,138 | 13,538 | 15,616 | 21,090 | 23,571 |
| Borrowings | 3,583 | 3,695 | 3,920 | 2,665 | 4,825 | 6,178 | 8,342 | 7,442 |
| Other Liabilities | 1,519 | 1,597 | 1,799 | 1,835 | 2,099 | 2,190 | 2,785 | 2,766 |
| Total Liabilities | 13,671 | 16,552 | 18,464 | 17,740 | 20,564 | 24,085 | 32,317 | 33,880 |
| Fixed Assets | 3,932 | 4,109 | 4,112 | 4,336 | 4,184 | 4,369 | 4,202 | 5,084 |
| CWIP | 675 | 553 | 570 | 384 | 739 | 634 | 1,188 | 621 |
| Investments | 4,195 | 6,404 | 6,471 | 5,118 | 4,879 | 7,283 | 11,492 | 11,478 |
| Other Assets | 4,868 | 5,486 | 7,310 | 7,902 | 10,761 | 11,798 | 15,435 | 16,696 |
| Total Assets | 13,671 | 16,552 | 18,464 | 17,740 | 20,564 | 24,085 | 32,317 | 33,880 |
| Category | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 581 | 1,181 | 2,227 | 1,272 | 1,078 | 2,000 | 3,114 | 2,234 |
| Cash from Investing Activity | -713 | 55 | -2,714 | 586 | -1,959 | -1,832 | -4,504 | 570 |
| Cash from Financing Activity | 65 | -967 | 255 | -1,710 | 827 | -301 | 1,384 | -2,580 |
| Net Cash Flow | -67 | 268 | -231 | 149 | -54 | -132 | -5 | 224 |
| Free Cash Flow | -140 | 589 | 1,701 | 755 | 420 | 1,434 | 2,257 | 1,351 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 55% | 97% | 108% | 80% | 60% | 71% | 58% | 84% |
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 74.98% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.02% | 75.01% |
| FIIs | 7.53% | 7.31% | 7.13% | 7.34% | 7.06% | 6.95% | 6.89% | 7.05% |
| DIIs | 10.61% | 10.95% | 11.09% | 10.86% | 11.08% | 11.20% | 11.27% | 11.28% |
| Government | 0.05% | 0.05% | 0.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 6.85% | 6.69% | 6.74% | 6.81% | 6.86% | 6.86% | 6.83% | 6.66% |
| No. of Shareholders | 3,65,356 | 3,71,619 | 3,86,127 | 3,96,105 | 4,03,266 | 4,18,314 | 3,99,251 | 3,82,067 |
| Category | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 128 | 141 | 89 | 106 | 147 | 160 | 197 | 270 |
| Inventory Days | 288 | 261 | 276 | 245 | 205 | 195 | 236 | 222 |
| Days Payable | 137 | 161 | 175 | 135 | 120 | 129 | 149 | 150 |
| Cash Conversion Cycle | 279 | 241 | 191 | 216 | 232 | 227 | 284 | 342 |
| Working Capital Days | 81 | 55 | 50 | 106 | 164 | 167 | 74 | 182 |
| ROCE % | 16% | 14% | 12% | 10% | 14% | 23% | 31% | 17% |
Zydus Lifesciences Ltd
₹1,12,020Cr.
₹1,123
₹1,232/836
30.7
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20.Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe
Quarterly results
Profit & loss
Shareholding trend
Balance sheet
Cash flows
Key ratios
Frequently asked questions
What is the market cap of ZYDUS LIFESCIENCES LTD (ZYDUSLIFE)?
The reported market capitalisation for ZYDUS LIFESCIENCES LTD (ZYDUSLIFE) is ₹1,12,020Cr. on Fincrux. Figures may update with market data and filings.
What is the current share price of ZYDUSLIFE?
The current price shown for ZYDUS LIFESCIENCES LTD (ZYDUSLIFE) on Fincrux is ₹1,123 with a 52-week high/low of ₹1,232/836.
What is the P/E ratio of ZYDUS LIFESCIENCES LTD (ZYDUSLIFE)?
The stock P/E for ZYDUS LIFESCIENCES LTD (ZYDUSLIFE) is 30.7 on Fincrux, with ROE at 16.5% and ROCE at 16.6%.
What were ZYDUSLIFE latest quarterly results?
For Jun 2026, ZYDUS LIFESCIENCES LTD (ZYDUSLIFE) reported sales ₹2,872 Cr and net profit ₹340 Cr (figures in ₹ crore unless noted).
What are ZYDUSLIFE annual sales and net profit?
For TTM, ZYDUS LIFESCIENCES LTD (ZYDUSLIFE) shows sales of ₹11,768 Cr and net profit of ₹3,515 Cr on the Fincrux profit & loss statement.
Who owns ZYDUS LIFESCIENCES LTD (ZYDUSLIFE)?
Latest shareholding for ZYDUS LIFESCIENCES LTD (ZYDUSLIFE) on Fincrux: Promoters 75.01% (Sep 2026), FIIs 7.05% (Sep 2026), DIIs 11.28% (Sep 2026), Government 0.00% (Sep 2026), Public 6.66% (Sep 2026).
Where can I find ZYDUS LIFESCIENCES LTD (ZYDUSLIFE) financials?
ZYDUS LIFESCIENCES LTD (ZYDUSLIFE) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.
Does Fincrux show ZYDUSLIFE balance sheet and cash flow?
Yes. The ZYDUS LIFESCIENCES LTD (ZYDUSLIFE) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.